These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

233 related articles for article (PubMed ID: 31208363)

  • 1. Computational analysis of receptor tyrosine kinase inhibitors and cancer metabolism: implications for treatment and discovery of potential therapeutic signatures.
    Li J; Halfter K; Zhang M; Saad C; Xu K; Bauer B; Huang Y; Shi L; Mansmann UR
    BMC Cancer; 2019 Jun; 19(1):600. PubMed ID: 31208363
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Exploiting receptor tyrosine kinase co-activation for cancer therapy.
    Tan AC; Vyse S; Huang PH
    Drug Discov Today; 2017 Jan; 22(1):72-84. PubMed ID: 27452454
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Receptor Tyrosine Kinase Phosphorylation Pattern-Based Multidrug Combination Is an Effective Approach for Personalized Cancer Treatment.
    Sun X; Song Q; He L; Yan L; Liu J; Zhang Q; Yu Q
    Mol Cancer Ther; 2016 Oct; 15(10):2508-2520. PubMed ID: 27458140
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Breaking Oncogene Addiction: Getting RTK/RAS-Mutated Cancers off the SOS.
    Sheffels E; Kortum RL
    J Med Chem; 2021 May; 64(10):6566-6568. PubMed ID: 33961431
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Radiolabeled probes targeting tyrosine-kinase receptors for personalized medicine.
    Altai M; Orlova A; Tolmachev V
    Curr Pharm Des; 2014; 20(14):2275-92. PubMed ID: 24025099
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Identification of metabolic vulnerabilities of receptor tyrosine kinases-driven cancer.
    Jin N; Bi A; Lan X; Xu J; Wang X; Liu Y; Wang T; Tang S; Zeng H; Chen Z; Tan M; Ai J; Xie H; Zhang T; Liu D; Huang R; Song Y; Leung EL; Yao X; Ding J; Geng M; Lin SH; Huang M
    Nat Commun; 2019 Jun; 10(1):2701. PubMed ID: 31221965
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Receptor Tyrosine Kinase-Targeted Cancer Therapy.
    Yamaoka T; Kusumoto S; Ando K; Ohba M; Ohmori T
    Int J Mol Sci; 2018 Nov; 19(11):. PubMed ID: 30404198
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Small tyrosine kinase inhibitors as key molecules in the expression of metalloproteinases by solid tumors.
    Stahtea XN; Kousidou OCh; Roussidis AE; Tzanakakis GN; Karamanos NK
    Connect Tissue Res; 2008; 49(3):211-4. PubMed ID: 18661345
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A systematic approach to therapeutic target selection in oesophago-gastric cancer.
    Paterson AL; Shannon NB; Lao-Sirieix P; Ong CA; Peters CJ; O'Donovan M; Fitzgerald RC
    Gut; 2013 Oct; 62(10):1415-24. PubMed ID: 22773546
    [TBL] [Abstract][Full Text] [Related]  

  • 10. SU14813: a novel multiple receptor tyrosine kinase inhibitor with potent antiangiogenic and antitumor activity.
    Patyna S; Laird AD; Mendel DB; O'farrell AM; Liang C; Guan H; Vojkovsky T; Vasile S; Wang X; Chen J; Grazzini M; Yang CY; Haznedar JO; Sukbuntherng J; Zhong WZ; Cherrington JM; Hu-Lowe D
    Mol Cancer Ther; 2006 Jul; 5(7):1774-82. PubMed ID: 16891463
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Oncogenic Receptor Tyrosine Kinases Directly Phosphorylate Focal Adhesion Kinase (FAK) as a Resistance Mechanism to FAK-Kinase Inhibitors.
    Marlowe TA; Lenzo FL; Figel SA; Grapes AT; Cance WG
    Mol Cancer Ther; 2016 Dec; 15(12):3028-3039. PubMed ID: 27638858
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Flavonoids as RTK inhibitors and potential anticancer agents.
    Teillet F; Boumendjel A; Boutonnat J; Ronot X
    Med Res Rev; 2008 Sep; 28(5):715-45. PubMed ID: 18080331
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Exploratory drug discovery in breast cancer patients: A multimodal deep learning approach to identify novel drug candidates targeting RTK signaling.
    Karampuri A; Kundur S; Perugu S
    Comput Biol Med; 2024 May; 174():108433. PubMed ID: 38642491
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Discovery and preclinical characterization of novel small molecule TRK and ROS1 tyrosine kinase inhibitors for the treatment of cancer and inflammation.
    Narayanan R; Yepuru M; Coss CC; Wu Z; Bauler MN; Barrett CM; Mohler ML; Wang Y; Kim J; Snyder LM; He Y; Levy N; Miller DD; Dalton JT
    PLoS One; 2013; 8(12):e83380. PubMed ID: 24386191
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Role of the Receptor Tyrosine Kinase Axl and its Targeting in Cancer Cells.
    Corno C; Gatti L; Lanzi C; Zaffaroni N; Colombo D; Perego P
    Curr Med Chem; 2016; 23(15):1496-512. PubMed ID: 27048336
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Targeting HSP90 in ovarian cancers with multiple receptor tyrosine kinase coactivation.
    Jiao Y; Ou W; Meng F; Zhou H; Wang A
    Mol Cancer; 2011 Sep; 10():125. PubMed ID: 21962244
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Activation of HER3 interferes with antitumor effects of Axl receptor tyrosine kinase inhibitors: suggestion of combination therapy.
    Torka R; Pénzes K; Gusenbauer S; Baumann C; Szabadkai I; Őrfi L; Kéri G; Ullrich A
    Neoplasia; 2014 Apr; 16(4):301-18. PubMed ID: 24862757
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Recent discovery and development of AXL inhibitors as antitumor agents.
    Liu Z; Chen L; Zhang J; Yang J; Xiao X; Shan L; Mao W
    Eur J Med Chem; 2024 Jun; 272():116475. PubMed ID: 38714043
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Acquired resistance to drugs targeting receptor tyrosine kinases.
    Rosenzweig SA
    Biochem Pharmacol; 2012 Apr; 83(8):1041-8. PubMed ID: 22227013
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Mechanisms of rapid cancer cell reprogramming initiated by targeted receptor tyrosine kinase inhibitors and inherent therapeutic vulnerabilities.
    Kleczko EK; Heasley LE
    Mol Cancer; 2018 Feb; 17(1):60. PubMed ID: 29458371
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.